Articlenpj aging2026
Serum uric acid, gout, cardiometabolic diseases, and multimorbidity: a prospective cohort study using multi-state model.
Article in npj aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Multimorbidity, particularly cardiometabolic multimorbidity (CMM), is a growing global health challenge, defined by the co-occurrence of cardiometabolic diseases (CMDs) like type 2 diabetes, ischemic heart disease, and stroke. While serum uric acid (SUA) and gout have been linked to various chronic conditions, their roles in multimorbidity and the CMM trajectory remain unexplored in large populations. Using data from over 400,000 UK Biobank participants, we explored the associations between SUA, gout, 36 chronic conditions, and multimorbidity. A multi-state model was applied to investigate SUA and gout's roles in the CMM trajectory, including transitions from CMD-free status to first CMD (FCMD), CMM, and death. Analyses were conducted for the overall population and stratified by sex. We observed that higher SUA levels and gout were associated with a higher likelihood of multimorbidity and multiple chronic conditions, particularly CMDs. Multi-state analysis revealed that both SUA and gout increased the risk of most transitions. Classifying FCMDs by specific CMDs further revealed distinct roles of SUA/gout in disease-specific transitions, even at the same stage. Sex-specific analyses showed a stronger impact in females compared to males. These findings highlight the importance of managing SUA levels and gout to prevent multimorbidity and slow CMM progression, particularly in females.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.